3
Announcements
Trials
Browse
Landscape
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Observational
1
Sponsor
Cancer Type
Thoracic
3
Classical hematology
2
Plasma cell
1
Other hematologic neoplasm
1
Myeloid
1
Lymphoid
1
Genitourinary
1
Gastrointestinal
1
Breast
1
Conditions
Multiple Myeloma
2
Lymphoma
2
Venous Thrombosis
1
Venous Thromboembolism
1
Vascular Diseases
1
Urogenital Neoplasms
1
Thromboembolism
1
Prostatic Neoplasms
1
Neoplasms
1
Myeloproliferative Disorders
1
Lymphoproliferative Disorders
1
Lymphatic Diseases
1
Lung Neoplasms
1
Leukemia
1
Intestinal Neoplasms
1
Hemostatic Disorders
1
Digestive System Neoplasms
1
Colorectal Neoplasms
1
Breast Neoplasms
1
Interventions
pembrolizumab
2
Trastuzumab
2
Specimen Handling
2
Magnetic Resonance Spectroscopy
2
Azacitidine
2
ulixertinib
1
trastuzumab biosimilar HLX02
1
trametinib
1
saracatinib
1
sapanisertib
1
relatlimab
1
pertuzumab
1
pemigatinib
1
palbociclib
1
osimertinib
1
orantinib
1
omipalisib
1
motexafin gadolinium
1
larotrectinib
1
ipatasertib
1
fludarabine
1
erdafitinib
1
defactinib
1
dabrafenib
1
copanlisib
1
cediranib
1
cc-486
1
capivasertib
1
binimetinib
1
adavosertib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Lung Neoplasms
×
Tinzaparin
×
Plasma cell
×
Clear all
NCT03099031
2019-12-16
PREDICARE
LEO Pharma
Completed
420 enrolled